CO-DIAGNOSTICS INC (CODX)

US1897631057 - Common Stock

0.78  +0.06 (+7.94%)

After market: 0.7999 +0.02 (+2.55%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CODX. CODX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for CODX as it has an excellent financial health rating, but there are worries on the profitability. CODX is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CODX had negative earnings in the past year.
CODX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CODX reported negative net income in multiple years.
In multiple years CODX reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a Return On Assets value of -57.04%, CODX is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
CODX has a Return On Equity (-64.73%) which is in line with its industry peers.
Industry RankSector Rank
ROA -57.04%
ROE -64.73%
ROIC N/A
ROA(3y)-8.57%
ROA(5y)-49.58%
ROE(3y)-8.75%
ROE(5y)-65.46%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CODX has a Gross Margin (49.30%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CODX has declined.
The Profit Margin and Operating Margin are not available for CODX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.84%
GM growth 5Y-12.46%

More info and screens

7

2. Health

2.1 Basic Checks

CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CODX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CODX has been increased compared to 5 years ago.
CODX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 0.03, we must say that CODX is in the distress zone and has some risk of bankruptcy.
CODX has a Altman-Z score (0.03) which is comparable to the rest of the industry.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.03
ROIC/WACCN/A
WACC9.21%

2.3 Liquidity

CODX has a Current Ratio of 6.92. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CODX (6.92) is better than 86.02% of its industry peers.
CODX has a Quick Ratio of 6.70. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
CODX's Quick ratio of 6.70 is amongst the best of the industry. CODX outperforms 87.63% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.7

More info and screens

4

3. Growth

3.1 Past

CODX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.63%, which is quite good.
CODX shows a strong growth in Revenue. In the last year, the Revenue has grown by 57.10%.
CODX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 179.41% yearly.
EPS 1Y (TTM)8.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)57.1%
Revenue growth 3Y-54.96%
Revenue growth 5Y179.41%
Sales Q2Q%-73.91%

3.2 Future

CODX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.68% yearly.
The Revenue is expected to decrease by -53.31% on average over the next years. This is quite bad
EPS Next Y-2.84%
EPS Next 2Y0.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-39.83%
Revenue Next 2Y-53.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CODX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CODX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CODX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CO-DIAGNOSTICS INC

NASDAQ:CODX (1/3/2025, 8:00:01 PM)

After market: 0.7999 +0.02 (+2.55%)

0.78

+0.06 (+7.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners14.58%
Inst Owner Change-3.1%
Ins Owners5.4%
Ins Owner Change5.96%
Market Cap24.91M
Analysts43.33
Price Target1.53 (96.15%)
Short Float %0.78%
Short Ratio1.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.28%
Min EPS beat(2)4.93%
Max EPS beat(2)59.63%
EPS beat(4)2
Avg EPS beat(4)-31.31%
Min EPS beat(4)-145.1%
Max EPS beat(4)59.63%
EPS beat(8)4
Avg EPS beat(8)-56.39%
EPS beat(12)7
Avg EPS beat(12)-35.66%
EPS beat(16)10
Avg EPS beat(16)-18.26%
Revenue beat(2)2
Avg Revenue beat(2)331.13%
Min Revenue beat(2)67.62%
Max Revenue beat(2)594.64%
Revenue beat(4)2
Avg Revenue beat(4)143.36%
Min Revenue beat(4)-84.96%
Max Revenue beat(4)594.64%
Revenue beat(8)3
Avg Revenue beat(8)186.9%
Revenue beat(12)4
Avg Revenue beat(12)115.2%
Revenue beat(16)7
Avg Revenue beat(16)89.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)150%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.4
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.23
BVpS2
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.04%
ROE -64.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.3%
FCFM N/A
ROA(3y)-8.57%
ROA(5y)-49.58%
ROE(3y)-8.75%
ROE(5y)-65.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.84%
GM growth 5Y-12.46%
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.73%
Cap/Sales 15.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.7
Altman-Z 0.03
F-Score4
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)139.91%
Cap/Depr(5y)225.38%
Cap/Sales(3y)8.3%
Cap/Sales(5y)15.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-2.84%
EPS Next 2Y0.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)57.1%
Revenue growth 3Y-54.96%
Revenue growth 5Y179.41%
Sales Q2Q%-73.91%
Revenue Next Year-39.83%
Revenue Next 2Y-53.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-288.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-266.27%
OCF growth 3YN/A
OCF growth 5YN/A